Pazopanib Noninferior to Sunitinib for Metastatic RCC

A head-to-head comparison of pazopanib and sunitinib for the treatment of metastatic renal cell carcinoma showed that the two drugs resulted in similar progression-free survival, but also indicated that pazopanib may have a favorable safety profile.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news